These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36546607)

  • 1. Validation of a diet-induced Macaca fascicularis model of non-alcoholic steatohepatitis with dietary and pioglitazone interventions.
    Camacho RC; Polidori D; Chen T; Chen B; Hsu HH; Gao B; Marella M; Lubomirski M; Beavers T; Cabrera J; Wong P; Nawrocki AR
    Diabetes Obes Metab; 2023 Apr; 25(4):1068-1079. PubMed ID: 36546607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis.
    Kohli R; Kirby M; Xanthakos SA; Softic S; Feldstein AE; Saxena V; Tang PH; Miles L; Miles MV; Balistreri WF; Woods SC; Seeley RJ
    Hepatology; 2010 Sep; 52(3):934-44. PubMed ID: 20607689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
    Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
    J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
    Malhotra P; Aloman C; Ankireddy A; Khadra H; Ooka K; Gill RK; Saksena S; Dudeja PK; Alrefai WA
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov; 313(5):G376-G385. PubMed ID: 28774869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
    Win S; Min RWM; Zhang J; Kanel G; Wanken B; Chen Y; Li M; Wang Y; Suzuki A; Aung FWM; Murray SF; Aghajan M; Than TA; Kaplowitz N
    Hepatology; 2021 Dec; 74(6):3127-3145. PubMed ID: 34331779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis.
    Ibrahim SH; Gores GJ; Hirsova P; Kirby M; Miles L; Jaeschke A; Kohli R
    Liver Int; 2014 Mar; 34(3):427-37. PubMed ID: 24256559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet.
    Kamada Y; Kiso S; Yoshida Y; Chatani N; Kizu T; Hamano M; Tsubakio M; Takemura T; Ezaki H; Hayashi N; Takehara T
    Am J Physiol Gastrointest Liver Physiol; 2011 Dec; 301(6):G1031-43. PubMed ID: 21885686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
    Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
    Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease.
    Christensen CU; Glavind E; Thomsen KL; Kim YO; Heebøll S; Schuppan D; Hamilton-Dutoit S; Würtz Heegaard C; Grønbæk H
    PLoS One; 2018; 13(3):e0192728. PubMed ID: 29522534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertical Sleeve Gastrectomy Attenuates the Progression of Non-Alcoholic Steatohepatitis in Mice on a High-Fat High-Cholesterol Diet.
    Whang E; Liu Y; Kageyama S; Woo SL; Yang J; Lee R; Li Z; Ji H; Chen Y; Kupiec-Weglinski JW
    Obes Surg; 2019 Aug; 29(8):2420-2429. PubMed ID: 30982168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of High-fat and High-cholesterol Diet on Major CYP Activities in the Liver].
    Suzuki S; Sato Y; Umegaki K; Chiba T
    Yakugaku Zasshi; 2016; 136(9):1297-305. PubMed ID: 27592832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.